EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan

Terufumi Kato iD, Tatsuya Ogura, Masashi Sato, Risa Kojima, Bingbing Song, Eisuke Horii, Kazuhiko Nakagawa

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf099 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Terufumi Kato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pyrimidines, Piperidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Biopharma Co, Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Tepotinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. The objective of this post-marketing surveillance (PMS) was to assess the safety and effectiveness of tepotinib in general clinical practice in Japan.

Methods

This multicenter, non-interventional PMS included patients with unresectable, advanced, or recurrent NSCLC with METex14 skipping alterations who received at least one dose of tepotinib. The primary endpoint was the incidence of adverse drug reactions (ADRs) identified as safety specifications (SS) for tepotinib according to the Japanese Risk Management Plan (ADRs of SS); i.e. interstitial lung disease (ILD), fluid retention, hepatic function disorder, renal impairment, and QT interval prolongation (classified by preferred term). The secondary endpoints were ADRs of SS in patient subgroups and the effectiveness of tepotinib in clinical practice. In total, 147 patients were included (median age 72.0 years).

Results

The incidence of ILD, fluid retention, hepatic function disorder, and renal impairment was 7.5%, 47.6%, 13.6%, and 36.1%, respectively; incidence of grade ≥3 ADRs of SS were 3.4%, 9.5%, 4.8%, and 2.7%, respectively. No instances of QT interval prolongation occurred. Four patients (2.7%) died due to ILD. The objective response rate was 51.0% [95% confidence interval (CI) 42.7, 59.3] and disease control rate was 77.6% (95% CI 69.9, 84.0).

Conclusions

Tepotinib was generally well tolerated and effective in patients with NSCLC and METex14 skipping alterations in general clinical practice in Japan; no new safety issues or concerns were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPyrimidinesPiperidinesNeoplasm Recurrence, LocalProto-Oncogene Proteins c-metAntineoplastic AgentsHumansMaleFemaleAgedMiddle AgedJapanProduct Surveillance, PostmarketingAged, 80 and overExonsAdultPyridazines

Stichwörter der Autor:innen

JapaneseMET receptor tyrosine kinasenon-small cell lung cancerpost-marketing surveillancetepotinib

Substanzen

tepotinibPyrimidinesPiperidinesProto-Oncogene Proteins c-metAntineoplastic AgentsPyridazines

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
  • Clinical Research Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
  • PMS Planning & Strategy, Merck Biopharma Co, Ltd. (an affiliate of Merck KGaA), 1.3.1 Azabudai, Minato-ku, Tokyo 106-0041, Japan.
  • Global Research & Development, Clinical Measurement Sciences, Biostatistics, Merck Biopharma Co, Ltd. (an affiliate of Merck KGaA), 1-3-1 Azabudai, Minato-ku, Tokyo 106-0041, Japan.
  • Global Patient Safety Japan, Merck Biopharma Co, Ltd. (an affiliate of Merck KGaA), 1-3-1 Azabudai, Minato-ku, Tokyo 106-0041, Japan.
  • Global Development Operations Japan, R&D, Merck Biopharma Co, Ltd. (an affiliate of Merck KGaA), 1-3-1 Azabudai, Minato-ku, Tokyo 106-0041, Japan.

ORCID-Profile: Terufumi Kato

Förderung

  • Merck Biopharma Co, Ltd

Zitieren

APA

Kato, T., Ogura, T., Sato, M., Kojima, R., Song, B., Horii, E., & Nakagawa, K. (2025). Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf099

Vancouver

Kato T, Ogura T, Sato M, Kojima R, Song B, Horii E, et al. Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf099

BibTeX
@article{Kato2025,
  author = {Kato, Terufumi and Ogura, Tatsuya and Sato, Masashi and Kojima, Risa and Song, Bingbing and Horii, Eisuke and Nakagawa, Kazuhiko},
  title = {Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf099}
}
Kostenlos starten →